

Association Between Regular Arrangement of Collecting Venules and Helicobacter Pylori Status in Routine Endoscopy

Cong Yuan

Affiliated Hospital of North Sichuan Medical College <https://orcid.org/0000-0002-1003-5819>

Xue-Mei Lin

Affiliated Hospital of North Sichuan Medical College

Yan Ou

Sichuan University West China School of Public Health

Lin Cai

Sichuan University West China School of Public Health

Qian Cheng

Sichuan University West China School of Public Health

Ping Zhou

Sichuan University West China School of Public Health

Juan Liao (✉ juanliao@scu.edu.cn)

Sichuan University West China School of Public Health <https://orcid.org/0000-0002-0386-1506>

Research article

Keywords: Helicobacter pylori, Gastrointestinal endoscopy, Gastric mucosa, Digestive system diagnostic techniques

DOI: <https://doi.org/10.21203/rs.3.rs-310799/v1>

License:  This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

Abstract

Background: The sensitivity of regular arrangement of collecting venules (RAC)-positive pattern for predicting *Helicobacter pylori* (*H. pylori*)-negative status greatly altered from 93.8% to 48.0% in recent two decades of various studies, while the reason behind it remained obscure. The aim of this study was to investigate the value of RAC as an endoscopic feature for judging *H. pylori* status in routine endoscopy and reviewed the underlying mechanism.

Methods: A prospective study with high-definition non-magnifying endoscopy was performed. RAC-positive and RAC-negative patients were classified according to the collecting venules morphology of the lesser curvature in gastric corpus. Gastric biopsy specimens were obtained from the lesser and greater curvature of corpus with normal RAC-positive or abnormal RAC-negative mucosal patterns. *H. pylori* status was established by hematoxylin and eosin staining and immunohistochemistry.

Results: 41 RAC-positive and 124 RAC-negative patients were enrolled from June 2020 to September 2020. The prevalence of *H. pylori* infection in patients with RAC-positive pattern and RAC-negative pattern was 7.3% (3/41) and 71.0% (88/124), respectively. Among all 124 RAC-negative patients, 36 (29.0%) patients were *H. pylori*-negative status. Ten patients (32.3%) demonstrated RAC-positive pattern in 31 *H. pylori*-eradicated cases. The sensitivity, specificity, positive predictive value, and negative predictive value of RAC-positive pattern for predicting *H. pylori* negative status were 51.4% (95%CI, 0.395-0.630), 96.7% (95%CI, 0.900-0.991), 92.7% (95%CI, 0.790-0.981), and 71.0% (95%CI, 0.620-0.786), respectively.

Conclusions: RAC presence can accurately rule out *H. pylori* infection of gastric corpus, and *H. pylori*-positive status cannot be predicted only by RAC absence in routine endoscopy.

Trial registration

The present study is a non-interventional trial.

Background

Helicobacter pylori (*H. pylori*) infection has been involved in over 60% of people in the world [1], which is a well-known risk factor for gastric disorders including active gastritis, peptic ulcer, MALT lymphoma and adenocarcinoma [2]. Invasive and noninvasive diagnostic tests for *H. pylori* have been extensively used in the clinical practice [3–5]. Among these methods, endoscopic approach is a potential benefit, which can provide real-time mucosal findings and prompt targeted biopsy. In recent years, the technological developments in magnifying endoscopy have allowed accurate diagnosis of *H. pylori* infection by evaluating the pit and vascular patterns [4]. However, magnifying endoscopy is less commonly used in routine clinical practice, and the procedure requires more time and expenditure, and specialized training. Therefore, diagnosis of *H. pylori* by non-magnifying endoscopy would still be of great interest to the general endoscopists.

By using non-magnifying endoscopy, regular arrangement of collecting venules (RAC) in the gastric body is generally recognized as a characteristic feature of a normal stomach without *H. pylori* infection [6]. In 2002, Yagi et al. [6] study had indicated that the presence of RAC at the distal part of the lesser gastric curvature for predicting *H. pylori*-negative normal stomach had more than 90% sensitivity and specificity. RAC pattern becomes invisible when gastric body mucosa was affected by *H. pylori* infection [7]. However, in numerous subsequent studies between 2004 and 2019, RAC absence was associated with *H. pylori* positive status in varied proportion from 47.3–94.4% among different cases [8–17]. Hence, the absence of RAC did not always indicate the positive status of *H. pylori*. So, the aim of our study was to investigate the prevalence of *H. pylori* in daily routine endoscopy without magnification, and evaluate the association between RAC pattern and *H. pylori* status.

Methods

Patients collection

We designed a prospective study including inpatients and outpatients who underwent upper GI endoscopy from June 2020 to September 2020. Consecutive patients with more than 18-years old were invited to attend the study. The following baseline characteristics were collected: age, sex, use of nonsteroidal anti-inflammatory drugs (NSAIDs), and history of *H. pylori* eradication in the last one year. Patients were excluded if they had previous partial gastrectomy, the diseases such as cirrhosis, chronic respiratory disorders, inflammatory bowel disease, collagen disease, and taken regular use of anticoagulants. The study protocol was approved by the institutional review board of West China Forth Hospital, Sichuan University (No. HXSY-EC-2020064). All participating patients gave written informed consents.

RAC pattern classification of corpus by non-magnifying endoscopy

After routine examination of the whole stomach by high-resolution endoscopy (GIF-H290; Olympus Optical Co. Ltd., Tokyo, Japan), the close-up observation of corpus was performed with a distance no more than 10 mm between the endoscope tip and mucosal surface, as described previously [13]. The collecting venules (CVs) morphology at the lesser gastric curvature was classified [18]: regular arrangement of CVs as RAC positive pattern (Figure 1a), obscure and irregular arrangement of CVs as RAC negative pattern. Some researchers further divided RAC-negative corpus mucosa into several types [3, 13-15, 19], such as spotty redness, diffuse redness, mosaic pattern, cleft-like appearance, untypical pattern, et al. (Figure 1b-f).

Biopsy specimens in the corpus and diagnosis of *H. pylori* infection

H. pylori infection in some patients only affected gastric antrum [6], and RAC appeared only in gastric body and fundus [7]. To ensure that *H. pylori* has infected the body of stomach, and explore the relationship between RAC pattern and corpus *H. pylori* status, two biopsy specimens were taken directly from

the lesser curvature and greater curvature in the corpus, avoiding some certain areas such as erosion, ulceration and gastric mucosa with a suspicion of intestinal metaplasia. These two sites are recommended by the update Sydney System for gastric corpus biopsy [20], and the gastric body greater curvature is a better site to detect current *H. pylori* infections [21].

The muscularis mucosae side of each biopsy specimen was stretched and fixed on filter paper, then bathed in a 10% formalin solution. 5- μ m sections of paraffin wax embedded tissues were stained. A diagnosis of *H. pylori* infection was achieved if bacillary and/or coccoid *H. pylori* was identified on histopathological examination with H&E assay and/or monoclonal immunohistochemistry (IHC) (mouse monoclonal antibody, MX014, MXB Biotechnologies, Fuzhou, China). In general, only rod-shaped *H. pylori* can be identified in the H&E sections considering that coccoid *H. pylori* may mimic other bacteria or cell debris on H&E preparations [21]. To avoid the interference of impurities in IHC sections, more than 5 spherical *H. pylori* per high power field was identified as coccoid *H. pylori* positive (Figure 2). All the assessment of gastric specimens was conducted by two pathologists, who were blinded to the clinical and endoscopic findings.

Statistical analysis

With the assumption that RAC would have a sensitivity of 90% with a confidence level of 95% and precision of 10%, a total of 158 patients were required. Continuous data with normal distribution were presented as mean \pm SD, continuous data without normal distribution were presented as median and interquartile range (IQR) and for nominal variables data were presented as percentages. The normality was tested using the Kolmogorov-Smirnov test. Regarding the association between RAC pattern and *H. pylori* status, the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and 95% confidence intervals (CI) were calculated [22]. Chi-square test and Mann-Whitney U-test were used to compare RAC-positive and RAC-negative group. The inter- and intraobserver reproducibility was calculated by using kappa values as described by Landis and Koch [23]. A *P* value of less than 0.05 was required for significance. All statistical analyses were performed using SPSS statistical software (version 22 SPSS Inc., Chicago, US).

Results

Study subjects and baseline characteristics

Demographics and endoscopic mucosal patterns were summarized in Table 1. A total of 165 patients were enrolled with a median age of 52 years (IQR 41, 61; range 18-79 years), and 107 (64.8%) patients were male. The age distribution of RAC-positive and RAC-negative groups was different, and RAC was more common in cases under 50 years old (*P* < 0.05). There was no difference in RAC between NSAIDs user and non-user groups (*P* < 0.05). 10 patients (32.3%) demonstrated RAC-positive pattern in 31 *H. pylori*-eradicated cases.

H. pylori infection status in RAC-positive and RAC-negative pattern

H. pylori positive rate was different between RAC-positive and RAC-negative group (7.3% versus 71.0%, *P* < 0.05). In RAC-positive group, *H. pylori*-negative status was revealed in 92.7% (38/41) patients. In RAC-negative group, 29.0% (36/124) of patients were *H. pylori*-negative status. Among 88 (71.0%, 88/124) *H. pylori*-positive patients in RAC-negative group, 80 had both spherical and rod shape, 5 had only spherical shape and 3 had only rod shape. In RAC-negative subgroups, the *H. pylori*-positive rate was 80.6%, 80.0%, 81.6%, 52.6% and 37.5% for spotty redness, diffuse redness, mosaic pattern, cleft-like appearance, and an untypical pattern, respectively (Table 2). RAC presence at the lesser gastric curvature was associated with a 51.4% sensitivity (95%CI, 0.395-0.630) and a 96.7% specificity (95%CI, 0.900-0.991) for estimating *H. pylori*-negative status. PPV and NPV were 92.7% (95%CI, 0.790-0.981) and 71.0% (95%CI, 0.620-0.786), respectively.

Inter- and intraobserver agreement assessment

The k-values for inter- and intraobserver agreement for the endoscopic mucosal patterns were significant. The k-values for inter- and intraobserver agreement for the assessment of *H. pylori* status were also significant (Table 3).

Discussion

RAC presence has been well known as a characteristic endoscopic feature in *H. pylori*-negative normal stomach [6, 7]. In 2002, Yagi et al. [6] researchers have indicated that the presence of RAC for predicting *H. pylori*-negative normal stomach had 93.8% sensitivity and 96.2% specificity. In many subsequent studies [8–17], the RAC-positive pattern also demonstrated a high specificity between 85.7% and 100%, however, the sensitivity of RAC-positive pattern varied from 93.5–48.0%. In our study, RAC presence has only 51.4% sensitivity and 71.0% NPV for predicting *H. pylori*-negative status in routine clinical practice despite a good specificity (96.7%) and PPV (92.7%). These studies strongly supported the idea that the presence of RAC in the lesser corpus can accurately identify *H. pylori*-negative gastric body mucosa [24], but RAC absence did not always point out *H. pylori*-positive corpus mucosa.

In clinical practice, many *H. pylori*-related and -unrelated factors can cause the disappearance of RAC, such as chronic active gastritis caused by current *H. pylori* infection, chronic inactive gastritis after *H. pylori* eradication, *H. pylori*-negative gastritis, and gastropathy induced by liver cirrhosis, et al [6, 25–28]. In patients with chronic active gastritis, in addition to the disappearance of RAC, *H. pylori* status can be assessed by combination with other endoscopic manifestations, such as diffuse redness, spotty redness and swelling of areae gastricae [14]. Shiota et al. [29] and Nordenstedt et al. [30] had found *H. pylori*-negative gastritis in 17.7% and 21% of patients with histologic gastritis. Although *H. pylori*-negative gastritis is a condition that cannot be ignored, the diagnosis process is complicated and difficult to apply in daily work [29, 30]. Thus, we have not further evaluated such patients with *H. pylori*-negative gastritis in the present study. In inclusion criteria, the patients with liver cirrhosis have been excluded. NSAIDs were also one of the common causes of gastropathy. Our results revealed that no significant differences in RAC pattern were found in a small group of patients treated with NSAIDs, which was consistent with previous studies [17].

H. pylori-eradicated cases have been arising considering the preventive effect of *H. pylori* eradication therapy for gastric cancer [31]. However, RAC will not reappear immediately after *H. pylori* eradication. Yagi et al. [26] have revealed that RAC did not recover for over one year in 68% subjects after successful *H. pylori* eradication. Garces-Duran et al. [17] also found that about half of past *H. pylori*-eradicated patients were RAC-negative. Thus, RAC would be invisible in a considerable proportion of *H. pylori*-eradicated patients. We found that RAC was still absent in about two-thirds of patients (67.7%, 21/31) with *H. pylori* eradication history. These results revealed that RAC absence did not always indicate *H. pylori*-positive status in patients with *H. pylori* eradication history. Although detailed medical records were very vital for identifying the eradicated cases, some patients still failed to provide past *H. pylori* eradication clearly. In addition, partially eradicated patients may come from unintended *H. pylori* sterilization because of the infectious diseases in other organs. Besides, *H. pylori* may be also naturally eradicated without bactericidal therapy. These conditions made it difficult for us to accurately judge the past infection of *H. pylori* in clinical practice. Therefore, we investigated the total *H. pylori* prevalence in RAC-negative patients, and found that only 71.0% (88/124) subjects were *H. pylori* positive. 29.0% (36/124) of patients were *H. pylori*-negative status although RAC disappeared, which resulting in the low sensitivity (51.4%) and NPV (71.0%).

In these reports [6, 8–17] on the relationship between RAC pattern and *H. pylori* status, the sensitivity of RAC varied greatly from 93.8–48.0%, which may be related to different baseline characteristics of the patients and multiple methods of *H. pylori* status judgment. Among the 11 studies, four studies [9, 11, 13, 17] simultaneously detected *H. Pylori* in gastric body and antrum by histological examination and rapid urease test (RUT), and showed that the sensitivity of RAC decreased from 92.8–49.0% due to the difference in baseline characteristics. For example, in Garces-Duran et al. [17] study the patients with NSAIDs usage and past *H. pylori* eradication were enrolled, and the sensitivity was only 49.0%. In the present study, we did not also exclude analogous patients and the sensitivity was low (51.4%). Even if the patients with *H. pylori* eradication history were excluded in inclusion criteria, the sensitivity was only 66.7% in Yan et al. [15] study and 48.0% in Kato et al. [14] study. Indeed, in clinical work, it is very difficult for us to completely exclude insidious past *H. pylori* infection, especially unintended *H. pylori* sterilization and spontaneous eradicators mentioned above. Interestingly, the two studies [14, 15] only detected *H. pylori* in gastric body by histology and/or RUT. Therefore, the prevalence of *H. pylori* could only reflect the *H. pylori* status in the corpus, which was similar to our study. One studies [10] merely detected *H. pylori* in the antrum by histology and RUT, which can not reveal the infection of *H. pylori* in gastric body because in some patients the infection only affected gastric antrum [6]. Indeed, it was not appropriate to use RAC in the body to predict *H. pylori* status in the antrum in this study.

RAC absence is one of the main manifestations of chronic active gastritis due to *H. pylori* current infection [6, 7, 12]. Gastric mucosal active inflammation should relieve shortly after eradication of *H. pylori*, however, RAC was still negative in some patients [17, 26]. Mild chronic inflammation in gastric mucosa can persist for more than 5 years after successful *H. pylori* eradication therapy in up to one-fifth of patients [32]. The appearance of RAC was the endoscopic manifestation of normal gastric corpus mucosa without pathologic changes [33, 34]. Saghier et al. [35] study has showed that foveolar length of corpus mucosa in *H. pylori* gastritis patients was significantly increased than that of normal *H. pylori*-uninfected gastric corpus. In a recent study from our team [36], we found that the prolongation of gastric foveolae could result in the invisibility of RAC. We revealed that in addition to *H. pylori* current infection, chronic inactive gastritis in *H. pylori*-eradicated patients can also cause RAC disappearing through the prolongation of gastric foveolae. Therefore, along with the increase of *H. pylori*-eradicated patients, the subjects with RAC-negative and *H. pylori*-negative entity are further accumulating, which can lead to decreasing sensitivity. Hence, only RAC disappearance was not a reliable feature to judge *H. pylori* positive status in daily practice. In fact, in Yagi et al. study [6], the predicting corpus mucosa of RAC presence was not only *H. pylori* negative status but also normal pathological features. However, in many studies [8–17], only *H. pylori* status was evaluated, ignoring gastric mucosa pathological abnormality, in particular the changes of gastric foveolae length. In a word, RAC presence was the endoscopic manifestation of normal gastric corpus mucosa with normal histology [33, 34], which can not only exclude *H. Pylori* infection, but also eliminate the pathological abnormalities of corpus mucosa caused by other factors.

Our study had several limitations: Firstly, our study only explored the relationship between RAC and *H. Pylori* infection in gastric corpus mucosa, and *H. pylori* status of gastric antrum mucosa was not evaluated. Therefore, *H. Pylori* status of gastric corpus cannot be represented the entire stomach. Secondly, histological detection of *H. pylori* can reduce the accuracy because of patchy distribution of the bacteria. Combination of multiple methods was helpful to more accurate detection of *H. Pylori* such as urea breath test, serological examination, PCR and culturing. However, PCR and *H. pylori* culturing was not convenient in daily clinical practice. In addition, urea breath test and serological examination cannot distinguish the patients in which the gastric body was only affected, and not be performed in the present study. Thirdly, RAC accuracy may be influenced by patient age [37]. We did not conduct age stratification analysis due to the limited sample size. Lastly, this was a single-center study, with a limited number of cases and a short time span. In future, more patients can be included to analyze different detective methods of *H. pylori* and different patient subgroups to strengthen our results.

Conclusions

The present study has demonstrated that RAC presence can accurately rule out the *H. pylori* infection of gastric corpus, but the positive status of *H. pylori* cannot be effectively predicted only by the absence of RAC in routine endoscopy. In patients with RAC-negative pattern, other endoscopic features should be combined to improve the diagnosis of *H. pylori*.

Abbreviations

H.pylori: *Helicobacter pylori*; RAC: regular arrangement of collecting venules; CVs: collecting venules; IHC: immunohistochemistry; IQR: interquartile range; NSAIDs: nonsteroidal anti-inflammatory drugs; CI: confidence interval; PPV: positive predictive value; NPV: negative predictive value; RUT: rapid urease test; UBT: urea breath test.

Declarations

Acknowledgements

Not applicable.

Authors' contributions

LJ designed the study. YC and OY conducted the experiments, analyzed data, and drafted the manuscript. LX and ZP performed the pathological assessment. YC, OY, CL, and CQ were involved in the collection of gastric specimens, data analysis, and reviewed the paper. All authors read and approved the final manuscript.

Funding

This work was supported by a grant from the International Cooperation Project of Sichuan Science and Technology Department (to Juan Liao, No.2020YFH0106).

Availability of data and materials

All data analyzed during this study are included in this published article.

Ethics approval and consent to participate

The study protocol was approved by the Institutional Review Board of West China Forth Hospital, Sichuan University (No. HXSJ-EC-2020064). All participating patients gave written informed consents.

Consent for publication

Not applicable.

Competing interests

Authors declare no conflicts of interest for this article.

Author details

¹ Department of Gastroenterology, Affiliated Hospital of North Sichuan Medical College, Nanchong 637000, Sichuan, China. ² Department of Pathology, Basic Medical College of North Sichuan Medical College, Nanchong 637000, Sichuan, China. ³ Department of Pathology, Affiliated Hospital of North Sichuan Medical College, Nanchong 637000, Sichuan, China. ⁴ Department of Gastroenterology, West China Forth Hospital, West China School of public health, Sichuan University, Chengdu 610041, China. ⁵ Department of Pathology, West China Forth Hospital, West China School of public health, Sichuan University, Chengdu 610041, China.

ORCID

Cong Yuan: <https://orcid.org/0000-0002-1003-5819>

References

1. Hooi JKY, Lai WY, Ng WK, Suen MMY, Underwood FE, Tanyingoh D, et al. Global Prevalence of *Helicobacter pylori* Infection: Systematic Review and Meta-Analysis. *Gastroenterology*. 2017;153(2):420–29. <https://doi.org/10.1053/j.gastro.2017.04.022>.
2. Chey WD, Wong BC, Practice Parameters Committee of the American College of G. American College of Gastroenterology guideline on the management of *Helicobacter pylori* infection. *Am J Gastroenterol*. 2007;102(8):1808–25. <https://doi.org/10.1111/j.1572-0241.2007.01393.x>.
3. Glover B, Teare J, Patel N. A systematic review of the role of non-magnified endoscopy for the assessment of *H. pylori* infection. *Endosc Int Open*. 2020;8(2):E105-E114. <https://doi.org/10.1055/a-0999-5252>.
4. Qi Q, Guo C, Ji R, Li Z, Zuo X, Li Y. Diagnostic Performance of Magnifying Endoscopy for *Helicobacter pylori* Infection: A Meta-Analysis. *PLoS One*. 2016;11(12):e0168201. <https://doi.org/10.1371/journal.pone.0168201>.
5. Godbole G, Megraud F, Bessede E. Review. Diagnosis of *Helicobacter pylori* infection. *Helicobacter*. 2020; 25 Suppl 1:e12735. <https://doi.org/10.1111/hel.12735>.
6. Yagi K, Nakamura A, Sekine A. Characteristic endoscopic and magnified endoscopic findings in the normal stomach without *Helicobacter pylori* infection. *J Gastroenterol Hepatol*. 2002;17(1):39–45. <https://doi.org/10.1046/j.1440-1746.2002.02665.x>.
7. Yagi K, Aruga Y, Nakamura A, Sekine A. Regular arrangement of collecting venules (RAC): a characteristic endoscopic feature of *Helicobacter pylori*-negative normal stomach and its relationship with esophago-gastric adenocarcinoma. *J Gastroenterol*. 2005;40(5):443–52. <https://doi.org/10.1007/s00535-005-1605-0>.
8. Nakayama Y, Horiuchi A, Kumagai T, Kubota S, Kobayashi M, Sano K, et al. Discrimination of normal gastric mucosa from *Helicobacter pylori* gastritis using standard endoscopes and a single observation site: studies in children and young adults. *Helicobacter*. 2004;9(2):95–9. <https://doi.org/10.1111/j.1083-4389.2004.00204.x>.
9. Anagnostopoulos GK, Yao K, Kaye P, Fogden E, Fortun P, Shonde A, et al. High-resolution magnification endoscopy can reliably identify normal gastric mucosa, *Helicobacter pylori*-associated gastritis, and gastric atrophy. *Endoscopy*. 2007;39(3):202–7. <https://doi.org/10.1055/s-2006-945056>.

10. Machado RS, Viriato A, Kawakami E, Patricio FR. The regular arrangement of collecting venules pattern evaluated by standard endoscope and the absence of antrum nodularity are highly indicative of *Helicobacter pylori* uninfected gastric mucosa. *Dig Liver Dis.* 2008;40(1):68–72. <https://doi.org/10.1016/j.dld.2007.08.003>.
11. Gonen C, Simsek I, Sarioglu S, Akpınar H. Comparison of high resolution magnifying endoscopy and standard videoendoscopy for the diagnosis of *Helicobacter pylori* gastritis in routine clinical practice: a prospective study. *Helicobacter.* 2009;14(1):12–21. <https://doi.org/10.1111/j.1523-5378.2009.00650.x>.
12. Hidaka N, Nakayama Y, Horiuchi A, Kato S, Sano K. Endoscopic identification of *Helicobacter pylori* gastritis in children. *Dig Endosc.* 2010;22(2):90–4. <https://doi.org/10.1111/j.1443-1661.2010.00943.x>.
13. Cho JH, Chang YW, Jang JY, Shim JJ, Lee CK, Dong SH, et al. Close observation of gastric mucosal pattern by standard endoscopy can predict *Helicobacter pylori* infection status. *J Gastroenterol Hepatol.* 2013;28(2):279–84. <https://doi.org/10.1111/jgh.12046>.
14. Kato T, Yagi N, Kamada T, Shimbo T, Watanabe H, Ida K, et al. Diagnosis of *Helicobacter pylori* infection in gastric mucosa by endoscopic features: a multicenter prospective study. *Dig Endosc.* 2013;25(5):508–18. <https://doi.org/10.1111/den.12031>.
15. Yan SL, Wu ST, Chen CH, Hung YH, Yang TH, Pang VS, et al. Mucosal patterns of *Helicobacter pylori*-related gastritis without atrophy in the gastric corpus using standard endoscopy. *World J Gastroenterol.* 2010;16(4):496–500. <https://doi.org/10.3748/wjg.v16.i4.496>.
16. Tongtawee T, Kaewpitoon S, Kaewpitoon N, Dechsukhum C, Loyd RA, Matrakool L. Correlation between gastric mucosal morphologic patterns and histopathological severity of *Helicobacter pylori* associated gastritis using conventional narrow band imaging gastroscopy. *Biomed Res Int.* 2015; 2015:808505. <https://doi.org/10.1155/2015/808505>.
17. Garces-Duran R, Garcia-Rodriguez A, Cordova H, Cuatrecasas M, Gines A, Gonzalez-Suarez B, et al. Association between a regular arrangement of collecting venules and absence of *Helicobacter pylori* infection in a European population. *Gastrointest Endosc.* 2019;90(3):461–66. <https://doi.org/10.1016/j.gie.2019.05.027>.
18. Nakagawa S, Kato M, Shimizu Y, Nakagawa M, Yamamoto J, Luis PA, et al. Relationship between histopathologic gastritis and mucosal microvasculature: observations with magnifying endoscopy. *Gastrointest Endosc.* 2003;58(1):71–5. <https://doi.org/10.1067/mge.2003.316>.
19. Nomura S, Terao S, Adachi K, Kato T, Ida K, Watanabe H, et al. Endoscopic diagnosis of gastric mucosal activity and inflammation. *Dig Endosc.* 2013;25(2):136–46. <https://doi.org/10.1111/j.1443-1661.2012.01357.x>.
20. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The Updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. *Am J Surg Pathol.* 1996; 20(10):1161-81. <https://doi.org/10.1097/00000478-199610000-00001>.
21. Lee JY, Kim N. Diagnosis of *Helicobacter pylori* by invasive test: histology. *Ann Transl Med.* 2015;3(1):10. <https://doi.org/10.3978/j.issn.2305-5839.2014.11.03>.
22. Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. *Stat Med.* 1998;17(8):857–72. [https://doi.org/10.1002/\(sici\)1097-0258\(19980430\)17](https://doi.org/10.1002/(sici)1097-0258(19980430)17).
23. Landis JR, Koch GG. The measurement of observer agreement for categorical data. *Biometrics.* 1977;33(1):159–74.
24. Li L, Jing J, Gao H, Zhang C, Lou H, Pan W. Regular arrangement of collecting venules under endoscopy for predicting a *Helicobacter pylori*-negative stomach: A systematic review and meta-analysis. *Gastroenterol Hepatol.* 2020. <https://doi.org/10.1016/j.gastrohep.2020.08.003>.
25. Yagi K, Nakamura A, Sekine A. Comparison between magnifying endoscopy and histological, culture and urease test findings from the gastric mucosa of the corpus. *Endoscopy.* 2002;34(5):376–81. <https://doi.org/10.1055/s-2002-25281>.
26. Yagi K, Nakamura A, Sekine A. magnifying endoscopy of the gastric body: a comparison of the findings before and after eradication of *helicobacter pylori*. *Digestive Endoscopy.* 2002;14(s1):76–82. <https://doi.org/10.1046/j.1443-1661.14.s1.10.x>.
27. Hayashi S, Saeki S. Endoscopic microvascular architecture of the portal hypertensive gastric mucosa on narrow band imaging. *Digestive Endoscopy.* 2007;19(3):116–23. <https://doi.org/10.1111/j.1443-1661.2007.00701.x>.
28. Genta RM, Lash RH. *Helicobacter pylori*-negative gastritis: seek, yet ye shall not always find. *Am J Surg Pathol.* 2010;34(8):e25–34. <https://doi.org/10.1097/PAS.0b013e3181e51067>.
29. Shiota S, Thrift AP, Green L, Shah R, Verstovsek G, Rugge M, et al. Clinical Manifestations of *Helicobacter pylori*-Negative Gastritis. *Clin Gastroenterol Hepatol.* 2017;15(7):1037–46.e3. <https://doi.org/10.1016/j.cgh.2017.01.006>.
30. Nordenstedt H, Graham DY, Kramer JR, Rugge M, Verstovsek G, Fitzgerald S, et al. *Helicobacter pylori*-negative gastritis: prevalence and risk factors. *Am J Gastroenterol.* 2013;108(1):65–71. <https://doi.org/10.1038/ajg.2012.372>.
31. Fukase K, Kato M, Kikuchi S, Inoue K, Uemura N, Okamoto S, et al. Effect of eradication of *Helicobacter pylori* on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. *Lancet.* 2008;372(9636):392–7. [https://doi.org/10.1016/S0140-6736\(08\)61159-9](https://doi.org/10.1016/S0140-6736(08)61159-9).
32. Veijola L, Oksanen A, Linnala A, Sipponen P, Rautelin H. Persisting chronic gastritis and elevated *Helicobacter pylori* antibodies after successful eradication therapy. *Helicobacter.* 2007;12(6):605–8. <https://doi.org/10.1111/j.1523-5378.2007.00549.x>.
33. Yao K, Iwashita A, Kikuchi Y, Yao T, Matsui T, Tanabe H, et al. Novel zoom endoscopy technique for visualizing the microvascular architecture in gastric mucosa. *Clin Gastroenterol Hepatol.* 2005;3(7 Suppl 1):23-6. [https://doi.org/10.1016/s1542-3565\(05\)00255-7](https://doi.org/10.1016/s1542-3565(05)00255-7).
34. Yao K. Gastric microvascular architecture as visualized by magnifying endoscopy: body and antral mucosa without pathologic change demonstrate two different patterns of microvascular architecture. *Gastrointest Endosc.* 2004;59(4):596–7. [https://doi.org/10.1016/s0016-5107\(03\)02825-6](https://doi.org/10.1016/s0016-5107(03)02825-6). author reply 97.

35. Saghier S, Schwarz SM, Anderson V, Gupta R, Heidarian A, Rabinowitz SS. Pediatric *Helicobacter pylori* gastropathy demonstrates a unique pattern of gastric foveolar hyperplasia. *Helicobacter*. 2018;23(3):e12487. <https://doi.org/10.1111/hel.12487>.
36. Yuan C, Lin XM, Ou Y, Cheng Q, Cai L, Zhou P, et al. Gastric foveolar elongation causes invisibility of regular arrangement of collecting venules in chronic active and inactive gastritis. *Helicobacter*. 2021;26(1):e12770. <https://doi.org/10.1111/hel.12770>.
37. Alaboudy A, Elbahrawy A, Matsumoto S, Galal GM, Chiba T. Regular arrangement of collecting venules: Does patient age affect its accuracy? *World J Gastrointest Endosc*. 2011;3(6):118–23. <https://doi.org/10.4253/wjge.v3.i6.118>.

Tables

Table 1 Baseline characteristics of the patients in current study

Characteristics	Total (n=165)	RAC positive (n=41)	RAC negative (n=124)	P value
Age, years (median, IQR)	52 (41, 61)	40 (30, 51)	49 (37, 58)	0.005
Age				
< 50 years	89 (53.9)	29	60	0.01
≥ 50 years	76 (46.1)	12	64	
Gender				
Male	107 (64.8)	28	79	0.59
Female	58 (35.2)	13	45	
NSAIDs				
Yes	31 (18.8)	11	20	0.39
No	100 (60.6)	36	64	
Unknown	34 (20.6)			
<i>H. pylori</i> status				
Positive	91 (55.2)	3	88	< 0.001
Negative	74 (44.8)	38	36	
<i>H. pylori</i> eradicated				
Yes	31 (18.8)	10	21	0.48
No	101 (61.2)	26	75	
Unknown	33 (20.0)			

IQR, interquartile range; NSAIDs, nonsteroidal anti-inflammatory drugs; RAC, regular arrangement of collecting venules.

Table 2 *H. pylori* infection status in endoscopic mucosal patterns

Mucosal patterns	Total	<i>H. pylori</i> status (n, %)		
		Negative	Positive	P value
RAC positive	41	38 (92.7)	3 (7.3)	< 0.001*
RAC negative	124	36 (29.0)	88 (71.0)	
Spotty redness	31	6 (19.4)	25 (80.6)	
Diffuse redness	20	4 (20.0)	16 (80.0)	
Mosaic	38	7(18.4)	31 (81.6)	
Cleft	19	9 (47.4)	10 (52.6)	
Untypical pattern	16	10 (62.5)	6 (37.5)	

RAC, regular arrangement of collecting venules. $P < 0.001^*$ RAC-positive versus RAC-negative group.

Table 3 Inter- and intraobserver agreement

	Interobserver agreement		Intraobserver agreement	
	% agreement	k value (95% CI)	% agreement	k value (95% CI)
RAC pattern	85.6	0.74 (0.71-0.78)	89.4	0.88 (0.78-0.96)
<i>H. pylori</i> status	92.7	0.86 (0.80-0.92)	93.5	0.94 (0.87-0.98)

The k-values for inter- and intraobserver agreement for mucosal patterns and *H. pylori* status were significant. CI, confidence interval.

Table 4 Summary of study characteristics on the association of RAC and *H. pylori* status

Author	Year	Reference methods								Number of patients	Eradicated patients	Sensitivity (%)	Specificity (%)
		Histology		RUT		UBT	Serology	Culture					
		Corpus	Antrum	Corpus	Antrum			Corpus	Antrum				
Yagi <i>et al</i> ⁶	2002	✓	✓	✓	✓			✓	✓	557	Unknown	93.8	96.1
Nakayama <i>et al</i> ⁸	2004	✓	✓	✓	✓	✓	✓			52	Excluded	93.5	100
Anagnostopoulos <i>et al</i> ⁹	2007	✓	✓	✓	✓					95	Unknown	92.8	100
Machado <i>et al</i> ¹⁰	2008		✓		✓					99	Excluded in 12 months	88.1	96.4
Gonen <i>et al</i> ¹¹	2009	✓	✓	✓	✓					129	Excluded	82.8	85.7
Yan <i>et al</i> ¹⁵	2010	✓		✓						112	Excluded	66.7	100
Hidaka <i>et al</i> ¹²	2010	✓	✓			✓	✓			87	Excluded	86.7	100
Cho <i>et al</i> ¹³	2013	✓	✓	✓	✓					617	Excluded	89.1	93.1
Kato <i>et al</i> ¹⁴	2013	✓								275	Excluded	48.0	93.1
Tongtawee <i>et al</i> ¹⁶	2015	✓		✓						200	Excluded in 2 months	53.0	100
Garces-Duran <i>et al</i> ¹⁷	2019	✓	✓	✓	✓					140	Included	49.0	100

UBT, urea breath test; RUT, rapid urease test; Corpus and antrum denoting the corresponding biopsy site.